United Therapeutics’ Earnings Call Signals Next Growth Phase

United Therapeutics Corp. ((UTHR)) has held its Q1 earnings call. Read on for the main highlights of the call.

United Therapeutics’ latest earnings call struck an optimistic tone, emphasizing powerful clinical wins and solid commercial momentum despite some operational bumps in the quarter. Management framed the period as a setup for the next growth leg, pointing to transformative Phase III data, expanding Tyvaso demand, and a multiyear path to materially higher revenue.

Q1 Results Anchor a $3–4 Billion Run-Rate Ambition

United Therapeutics reported Q1 2026 revenue of $782 million, including $458 million from Tyvaso, underscoring the franchise’s central role in the story. Management expects a near-term return to sequential growth and is targeting a revenue run rate climbing from roughly $3 billion today to $4 billion by the end of 2027.

Tyvaso DPI Fuels Demand as Higher Doses Gain Traction

Tyvaso DPI was again the main volume engine, delivering about 9% year-over-year growth and five consecutive months of rising patient shipments. Prescriber referrals and prescriptions are now roughly back to pre-YUTREPIA levels, with growing use of higher-dose capsules and combination kits supporting both adherence and revenue per patient.

Ralinepag’s ADVANCE OUTCOMES Data Reframe the PAH Market

The standout clinical story was ADVANCE OUTCOMES, where oral ralinepag cut disease progression roughly threefold versus background therapy and beat selexipag on key hazard ratios. With durable benefits out to four years, management sees a multibillion-dollar opportunity and believes ralinepag could double the treated PAH population to more than 30,000 within two years of launch.

TETON 1 & 2 Position Tyvaso as a Potential IPF Growth Engine

Both TETON trials of nebulized Tyvaso in idiopathic pulmonary fibrosis were described as resounding successes, with meaningful forced vital capacity gains versus today’s therapies. The company plans to file a supplemental application by late summer, and under a standard review is planning for a launch by the second quarter of next year, opening a sizable new addressable market.

RALDPI Emerges with an Aggressive Development Timeline

Management also pulled back the curtain on inhaled ralinepag (RALDPI), initiated about six months ago in partnership with MannKind. Formulation work is done, toxicology-supply manufacturing is underway, and after a positive pre-IND interaction, United Therapeutics expects to start and complete a Phase I study before year-end, targeting a once-daily inhaled profile.

Commercial Build-Out Targets PAH, PH-ILD and IPF Expansion

To support impending launches across PAH and lung-fibrosis indications, the company is adding sales force capacity mid-year. Management stressed confidence in its commercial engine and reiterated expectations for sustained double-digit long-term growth as it broadens its reach in PH-ILD, PAH and the projected new IPF segment.

Seasonal and Operational Issues Weighed on Q1 but Are Resolved

The quarter was not without pressure, as typical seasonality combined with severe winter weather and pharmacy disruptions slowed new patient starts, particularly in February. Executives said those operational issues have now been fixed, reinforcing their view that Q1 softness is transitory rather than structural.

Nebulized Tyvaso Trails DPI as Mix Shifts

While overall Tyvaso demand was solid, the legacy nebulized formulation “lagged a little bit,” tempering consolidated growth in the quarter. The trend highlights an ongoing mix shift toward DPI, which offers convenience advantages but also leaves investors watching how the company balances and protects the full franchise.

Regulatory, Bridging Studies and Device Filings Add Timing Risk

Management was candid that its ambitious pipeline of new formulations and devices requires additional regulatory interactions and bridging work. Sample sizes, study durations and final pathways for Tyvaso DPI bridging and RALDPI submissions are still being refined, introducing some uncertainty around the exact timing of approvals and launches.

Safety Limits May Shape Oral Versus Inhaled Positioning

The company also acknowledged that systemic vasodilators can be problematic in some PH-ILD and IPF patients due to ventilation-perfusion concerns. That safety reality may cap oral uptake in certain lung populations and could reinforce inhaled approaches like Tyvaso and RALDPI as better suited for more fragile respiratory cohorts.

Growth Targets Hinge on Smooth Regulatory Execution

Key projections—including a potential mid-next-year ralinepag launch, a second-quarter next-year launch for Tyvaso in IPF under standard review, and a revenue run rate moving to $4 billion by 2027—depend on timely regulatory reviews. Management believes recent pivotal data strongly support approvals, but investors should recognize that these timelines remain sensitive to review outcomes.

Guidance Highlights a Steady Climb with Big Clinical Catalysts

Looking ahead, United Therapeutics reaffirmed expectations for a return to sequential growth, supported by five months of rising patient shipments and normalized prescription trends. The company’s roadmap includes a summer filing for Tyvaso in IPF, a potential mid-next-year launch for oral ralinepag, completion of a Phase I study for inhaled ralinepag this year, and an ambition to grow the revenue run rate well beyond $4 billion as new indications scale.

United Therapeutics used this call to frame Q1 as a launching pad rather than a peak, pairing solid Tyvaso-driven revenue with some of the most compelling clinical data the PAH and IPF spaces have seen in years. If it can navigate regulatory hurdles and execute on multiple launches, the company appears positioned for sustained, double-digit growth and a step-change in its long-term earnings power.